(Q35835138)

10 August 2017

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer (English)

1 reference

10 August 2017

phase I clinical trial

0 references

1 reference

1 reference

N Steele

1

1 reference

10 August 2017

A Anthony

2

1 reference

10 August 2017

M Saunders

3

1 reference

10 August 2017

B Esmarck

4

1 reference

10 August 2017

E Ehrnrooth

5

1 reference

10 August 2017

P E G Kristjansen

6

1 reference

10 August 2017

A Nihlén

7

1 reference

10 August 2017

L T Hansen

8

1 reference

10 August 2017

J Cassidy

9

1 reference

10 August 2017

language of work or name

English

0 references

publication date

7 February 2012

1 reference

British Journal of Cancer

10 August 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

10 August 2017

106

1 reference

10 August 2017

5

1 reference

10 August 2017

793-798

1 reference

Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

Cetuximab for the treatment of colorectal cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

Cetuximab: in the treatment of metastatic colorectal cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305963

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

27 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.599

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.599

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.599

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22315057

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.599

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22315057

1 reference